GATX vs CAI vs EXAS vs ILMN vs PACB

For growth investors, Caris Life Sciences, Inc.

(CAI) is the stronger pick with 97. 0% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). GATX Corporation (GATX) offers the better valuation at 20. 1x trailing P/E (18. 3x forward), making it the more compelling value choice. Analysts rate GATX Corporation (GATX) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GATX Corporation (GATX) is the cheapest at 20.

1x versus Illumina, Inc. at 25. 5x. On forward P/E, GATX Corporation is actually cheaper at 18. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: GATX Corporation wins at 0. 83x versus Illumina, Inc. 's 6. 33x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, GATX Corporation (GATX) delivered a total return of +87.

5%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: EXAS returned +1669% versus PACB's -81. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 1915% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Caris Life Sciences, Inc. (CAI) carries a lower debt/equity ratio of 66% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Caris Life Sciences, Inc.

(CAI) is pulling ahead at 97. 0% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, CAI leads at 46. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GATX leads at 30. 7% versus -348. 5% for PACB. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, GATX Corporation (GATX) is the more undervalued stock at a PEG of 0. 83x versus Illumina, Inc. 's 6. 33x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, GATX Corporation (GATX) trades at 18. 3x forward P/E versus 582. 8x for Exact Sciences Corporation — 564. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAI: 44. 9% to $28. 75.

In this comparison, GATX (1.

4% yield) pays a dividend. CAI, EXAS, ILMN, PACB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GATX (Industrials) and CAI (Healthcare) and EXAS (Healthcare) and ILMN (Healthcare) and PACB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GATX is a small-cap quality compounder stock; CAI is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; ILMN is a mid-cap quality compounder stock; PACB is a small-cap quality compounder stock. GATX pays a dividend while CAI, EXAS, ILMN, PACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.